Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

LTX-315 × Dermatologic × 1 year × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1 Dermatologic 1

Conditions

Interventions

pembrolizumab 141 Nivolumab 126 Ipilimumab 74 Cyclophosphamide 40 Specimen Handling 37 Magnetic Resonance Spectroscopy 34 cemiplimab 32 Biopsy 28 fludarabine 25 trametinib 23 relatlimab 19 Interleukin-2 19 fludarabine phosphate 18 binimetinib 18 atezolizumab 18 Radiosurgery 18 Opdualag 18 dabrafenib 17 aldesleukin 16 Radiotherapy 16 CTLA-4 Antigen 16 Blood Specimen Collection 15 encorafenib 14 Immunoglobulin G 12 Bevacizumab 12 lenvatinib 11 avelumab 11 Fluorouracil 11 Disulfides 11 Cisplatin 10

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04796194 2025-11-20

ATLAS-IT-05

Lytix Biopharma AS

Phase 2 Completed

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡